.svg)
We develop
cures instead of treatments
About us
Genewity is a pioneering biotech start-up focused on advanced thymus-driven therapies for immune reconstitution. Supported by the extensive business expertise of our management and advisors, we are at the forefront of developing and commercialising breakthrough therapies. With over 150 years of combined experience in immunology and gene therapy, our team is uniquely positioned to drive advancements in the field..
.svg)
Vision
Our vision is to unlock the unrealised potential of restoring immune function to make a difference in the lives of patients worldwide. We pioneer innovative gene-modified cell therapies, bridging academic excellence and clinical application. By leveraging intellectual property, we transfer value and knowledge to set new industry standards with patient-centric treatments and make a global impact.
Mission
Our mission is to save and enhance lives by developing cutting-edge autologous gene-modified cell therapies to restore immune function in patients with immune disorders.
Supported by
-min.png)
Management & Advisors
Arno Bisschop, MD,
PhD, MSc
PhD, MSc
Chief Executive Officer
.jpg)
Willem-Jan Krebber, PhD
Chief Operating Officer
Ir. Bart Bergstein
Chief Financial Officer
.jpg)
Max Renes, MPhil, MSc
Chief Business Officer
.jpg)
Rob Posthumus, LL.M
Chief Legal Officer
Prof. Eric Claassen
Chief Business Advisor
Katja Jansen, PhD
Business Developer & Project
Manager
Manager
Drs. Johan Renes
Strategic Advisor Intellectual
Property
Property
Hadil Es-Sbai, MSc
Strategic Advisor Clinical
Development
Development
Prof. Sander van
Deventer
Deventer
Strategic Advisor Business
Development
Development
Jelle Feddema, MSc
Business Developer & Project
Manager
Manager
Scientific team
Aline Zbinden, PhD
Chief Technology Officer
Elselien Frijlink, PhD
Senior Scientist
Dyah Karjosukarso, PhD
Senior Scientist
Jiayi Miao, MSc
Research Technician
Marie van der Weide,
BSc
BSc
Research Technician
Saskia Bunschuh, MSc
Research Technician
Teun Been, MSc
Research Technician
.jpg)
Kirsten Lodder, BSc
Research Technician
Prof. Frank Staal
Chief Scientific Advisor
Prof. Arjan Lankester
Chief Medical Advisor
Technology
Genewity harnesses cutting-edge biotechnology to develop autologous thymus tissue from patient cells, aiming to restore the immune system with minimal rejection risk. By targeting underlying thymic defects, our innovative gene modification and cell therapy techniques provide critical solutions for treating severe immunedeficiencies. In close collaboration with leading institutions like Leiden University Medical Centre, we focus on rigorous preclinical and clinical research to deliver transformative therapies, enhancing patient well-being and healthcare outcomes.
Product pipeline
Product
i-Thymus
i-TOL
Indications
congenital athymia
undisclosed
Location
EU
EU
Discovery
Preclinical
Phase I/II
Phase III
Product pipeline
Product
i-Thymus
i-TOL
Indications
congenital athymia
undisclosed
Location
EU
EU
Discovery
Product pipeline
Programme
discovery-preclinical-phase1-phase2-phase3
i-Thymus
preclinical stage
i-TOL
discovery stage
News
Careers
There are currently no vacancies.
Open applications welcome
We always welcome open applications. If you are a talented individual interested in contributing to our mission, please send your CV and motivation letter to our CEO at:
a.bisschop@genewity.tech.
a.bisschop@genewity.tech.
About Genewity
Genewity B.V., founded in 2022 and based at BioScience Park in Leiden, the Netherlands, is a pioneering biotech company focused on developing autologous thymus tissue de novo. Our team leverages a wealth of scientific and business experience in cell and gene therapies. Genewity has been awarded several grants, including the prestigious EIC Accelerator. We collaborate in various international consortia with world-renowned partners in academia and industry. Currently in the preclinical development stage, we are raising Series A funding to advance our technology to clinical application.
Contact
If you have any questions, please feel free to contact us at the following email address:
info@genewity.tech
Disclaimer
This website may contain forecasts, projections, goals, plans, and other forward- looking statements regarding Genewity B.V., Genewity Innovations Holding B.V., and affiliates’ financial results and other data. Such forward-looking statements are based on the Company's assumptions, estimates, outlook, and other judgments made in light of information available at the time of preparation of such statements and involve both known and unknown risks and uncertainties. Accordingly, forecasts, plans, goals, and other statements may not be realised as described, and actual financial results, success or failure, or progress of development, and other projections may differ materially from those presented herein.
We strive to comply with WCAG 2.1 standards to ensure our website is accessible to everyone.
We strive to comply with WCAG 2.1 standards to ensure our website is accessible to everyone.
